OTX1 antibody - C-terminal region (P100958_P050)
- Known as:
- OTX1 (anti-) - C-terminal region (P100958_P050)
- Catalog number:
- p100958_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- OTX1 antibody - C-terminal region (P100958_P050)
Related genes to: OTX1 antibody - C-terminal region (P100958_P050)
- Gene:
- OTX1 NIH gene
- Name:
- orthodenticle homeobox 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p15
- Locus Type:
- gene with protein product
- Date approved:
- 1994-02-08
- Date modifiied:
- 2015-08-25
Related products to: OTX1 antibody - C-terminal region (P100958_P050)
Related articles to: OTX1 antibody - C-terminal region (P100958_P050)
- Research findings suggest that advanced paternal age is associated with an increased risk of autism spectrum disorder (ASD) in children. The biological process behind this father-to-child inheritance of a disease may be driven by sperm epigenetic marks. This has been suggested earlier, but the identification of epigenomic regions responsible for these age-related responses have not been further elaborated. To identify sperm-specific marks, we conducted an epigenome-wide association study in sperm from 63 men, using the Illumina 450K array. Linear regression modeling was applied to identify differentially methylated CpGs (DMCs) by age; we controlled for body mass index, patient status, and multiple testing. We found 14,622 statistically significant age-related DMCs; most (69%) were inversely correlated. We identified 95 imprinted genes and emphasized 747 age-related DMCs adjacent to an imprint control region (ICR). Altered methylation patterns in ICRs may result in disturbed expression of imprinted genes and are suspected to be at the origin of several diseases in offspring, including neurodevelopmental disorders. Mapping our results to other databases revealed the following set of imprinted genes linked to ASD: , and Further research on these genes could help understand the contribution of paternal age on the development of autism. A change in DNA methylation levels in ICRs before conception may contribute to the heterogeneity and complexity of ASD. Measured DNA methylation effect sizes were subtle, but small epigenetic disturbances in sperm may be important on a population level, especially if men continue delaying fatherhood. Public health would benefit from the development of preventive and educational programs. - Source: PubMed
Publication date: 2025/12/29
Casella EugeniaDepovere JanaDelger ChantalButynets MariiaAntczak PhilippPrice ThomasJirtle Randy LMurphy Susan KHoyo CathrineSoubry Adelheid - Bladder urothelial carcinoma (BLCA) is a common malignant tumor with high invasiveness and recurrence rates, underscoring the need for early diagnosis and effective monitoring. Current diagnostic methods, such as invasive cystoscopy and low-sensitivity urine cytology, have limitations. Oncogene hypermethylation plays a key role in tumorigenesis and progression. However, DNA methylation in BLCA remain underexplored. Identifying and validating new DNA methylation markers in urine samples is crucial to enhance early detection accuracy. In this study, we identified three novel BLCA DNA methylation biomarkers (HIST1H3J, NKX2-4, and YBX3P1 genes), and compared with six known markers (ONECUT2, OTX1, POU4F2, SOX1, TWIST1, VIM). Real-time quantitative methylation-specific PCR (qMSP) was used to detect the methylation levels of biomarkers in 319 urine samples from patients with suspected BLCA. The individual biomarkers of HIST1H3J, NKX2-4, and YBX3P1 achieved Areas Under the Curve (AUCs) of 0.892, 0.914 and 0.871, with accuracies of 84.80%, 85.38% and 81.29%, respectively. In comparison, the six known markers exhibited AUCs ranging from 0.850 to 0.939 and the accuracies of 81.87%-88.30%. These methylation markers can not only identify high-grade BLCA but also low-grade BLCA, highlighting their potential clinical utility. Notably, a four-gene panel (ONECUT2, SOX1, TWIST1 and NKX2-4) significantly improved the detection performance, with an AUC of 0.971 and an accuracy of 92.39%. Our results provide three new DNA methylation markers for BLCA and propose a urine-based DNA methylation detection panel for non-invasive clinical diagnosis. - Source: PubMed
Publication date: 2025/12/19
Shi CongXu JiangleiChen QinyuGao XuejuanChen LinJin ChunyuYu ZhixianDou Xiaobing - Zygotic genome activation is tightly associated with the modulation of chromatin accessibility via maternal transcription factors. Understanding how chromatin accessibility is established and identifying key maternal regulators are crucial to comprehending this process. Here, by developing CANTAC-seq, we generate a genome-wide map of accessible chromatin of early Xenopus tropicalis embryos and find that the open chromatin landscape is progressively established at cis-regulatory elements during zygotic genome activation. Based on the motif analysis and perturbation experiments, we demonstrate that E2f1 maintains a repressive chromatin environment and inhibits zygotic gene transcription before the mid-blastula transition. Moreover, we identify that Otx1, another maternal transcriptional activator, coordinates with E2f1 in regulating chromatin accessibility and zygotic genome activation. Together, E2f1 and Otx1 determine the timely expression of a subset of genes required for zygotic gene transcription and germ layer differentiation. - Source: PubMed
Publication date: 2025/11/18
Cui HuanhuanLiang WeizhengShi ZhaoyingZhang LumingLi GuipengChen RuiTian ChiGan DiwenShi XinyaoSun ZhiyuanZhu QionghuaFang LiangHuang HongdaHu YuhuiChen YonglongChen Wei - This study aims to utilize multi-omics high-throughput sequencing data, including ATAC-seq and RNA-seq data from TCGA, GTEx, and GEO databases, to construct predictive and prognostic models for lung adenocarcinoma (LUAD) and identify potential biomarkers. We first obtained LUAD ATAC-seq data from TCGA and identified differential chromatin regions and genes through functional analysis. Differential peaks (DPs) potentially influencing LUAD progression were determined by analyzing patients at different stages, and these DPs were annotated to the genome to obtain differential peak genes (DPGs). We then integrated RNA-seq data from GTEx and TCGA to identify differentially expressed genes (DEGs) at the mRNA level, and by intersecting DEGs with DPGs, we identified 337 consensus genes (CGs). Using random forest and LASSO algorithms, we screened the CGs and constructed a predictive model comprising nine predictive-related genes (Pre-RGs), which was validated with an external dataset (GSE140343). Additionally, through Kaplan-Meier and Cox analyses combined with LASSO, five prognostic-related genes (Pro-RGs) were identified and used to establish a prognostic Cox proportional hazards model, also validated by GSE140343. Single-cell dataset analysis examined the expression of Pre-RGs and Pro-RGs across immune cell types, and further meta-analysis in the LCE database verified their expression differences and prognostic significance. Furthermore, we sequenced cell-free RNAs (cfRNAs) from 50 plasma samples (25 early-stage lung cancer and 25 benign pulmonary disease cases) to validate early cancer detection. Overall, we identified signatures including , , , , , , , , , , , , , and , which show potential as drug targets and biomarkers for predicting LUAD development, prognosis, and early detection. - Source: PubMed
Publication date: 2025/11/10
Lu ZhendongBao PengfeiWang TaiweiHu KairuiZhang LinaYi LingPan YuanmingLi WeiyingLu Zhi JohnWang JinghuiRuan Junzhong - Circulating tumor DNA (ctDNA) is a promising biomarker for early cancer detection; however, the optimal biomarker approach for early detection of hepatocellular carcinoma (HCC) remains unclear. Furthermore, current next-generation sequencing-based detection methods remain costly and complex, limiting their clinical utility for high-risk population screening. Hence, this study compared ctDNA mutation and methylation for HCC detection and aimed to develop a clinically accessible assay. A total of 1965 participants, including 629 HCC and 1336 control participants, were enrolled in five centers. Parallel ultra-deep targeted sequencing and targeted bisulfite sequencing revealed that a methylation-based ctDNA model significantly outperformed the mutation model in detecting HCC (sensitivity, 92.1% vs. 63.7%; P < 0.001), with no added benefit from combining both markers. We subsequently developed a multiplex PCR-based bisulfite amplicon sequencing assay (MBA-seq) using 25 selected methylation markers, achieving high diagnostic accuracy (AUC = 0.958, sensitivity = 86.7%, specificity = 90.1%) in the testing set. Further refinement through AUC-based selection yielded a two-marker panel (OTX1 and HIST1H3G) adapted into a quantitative methylation-specific PCR assay, designated HCCtect. This optimized model showed robust performance (AUC = 0.925, sensitivity = 78.4%, specificity = 93.0%), significantly surpassing alpha-fetoprotein (P < 0.001) while comparable with MBA-seq. HCCtect also demonstrated efficacy in early-stage HCC detection (sensitivity = 69.5%) and discrimination from chronic hepatitis B or liver cirrhosis (specificity = 93.0%). These findings establish ctDNA methylation as a superior approach over mutation analysis and highlight HCCtect as a promising non-invasive tool for HCC detection and high-risk population monitoring. - Source: PubMed
Publication date: 2025/10/29
Guo DezhenHuang AoSun JianlongZhang ShiyuCheng JianwenJiang RuijingfangWang YupengChen HuihaoZhang FengmingPeng JiaxiYuan JieWang JiefeiGuo HongyingChen ZhongChen YongjunChen XuxiaoZhu ShidaFan JiaWang YuyingYang XinrongZhou Jian